高级检索
当前位置: 首页 > 详情页

Raf kinase inhibitor protein mediated signaling inhibits invasion and metastasis of hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Hepatobiliary Surg, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China [2]Hebei Inst North, Hosp 1, Dept Surg Oncol, Beijing, Peoples R China
出处:
ISSN:

关键词: Hepatocellular carcinoma RKIP Signaling transduction Invasion Metastasis

摘要:
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer with high mortality and poor prognosis. Mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-KB) signaling pathways have been implicated in promoting tumor cell proliferation and invasion of HCC cells. Methods: As a potential inhibitor of tumor metastasis, the role of Raf kinase inhibitor protein (RKIP) in HCC development and the functional relevance with MAPK and NF-kappa B signaling pathways were investigated. The levels of IMP expression were examined in human HCC tissues and correlated with tumor stages and metastatic status. Function of RKIP in cellular proliferation, migration, invasion and apoptosis was investigated in HCC cell lines by either overexpressing or knocking down RKIP expression. Mouse xenograft model was established to assess the effect of RKIP expression on tumor growth. Results: Our results demonstrated decreased IMP expression in HCC tissues and a strong correlation with tumor grade and distant metastasis. Manipulation of RKIP expression in HCCLM3 and HepG2 cells indicated that RKIP functioned to inhibit HCC cell motility and invasiveness, and contributed to tumor growth inhibition in vivo. Mechanistic studies showed that the function of RKIP was mediated through IVIAPK and NF-kappa B signaling pathways. However, cell type-dependent RKIP regulation on these two pathways was also suggested, indicating the complex nature of signaling network. Conclusion: Our study provides a better understanding on the molecular mechanisms of HCC metastasis and sets the foundation for the development of targeted therapeutics for HCC. (C) 2015 Published by Elsevier B.V.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 2 区 生物
小类 | 2 区 生化与分子生物学 2 区 生物物理
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生物物理 4 区 生化与分子生物学
JCR分区:
出版当年[2016]版:
Q1 BIOPHYSICS Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版:
Q2 BIOPHYSICS Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Hepatobiliary Surg, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Hepatobiliary Surg, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China [*1]Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050011, Hebei, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39767 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号